BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,222 | -90.3% | 96,060 | 0.0% | 0.00% | – |
| Q2 2023 | $197,884 | -37.6% | 96,060 | 0.0% | 0.00% | – |
| Q1 2023 | $316,998 | +0.6% | 96,060 | -50.0% | 0.00% | – |
| Q4 2022 | $315,076 | -25.9% | 192,120 | +100.0% | 0.00% | – |
| Q3 2022 | $425,000 | +60.4% | 96,060 | 0.0% | 0.00% | – |
| Q2 2022 | $265,000 | -18.0% | 96,060 | 0.0% | 0.00% | – |
| Q1 2022 | $323,000 | -6.9% | 96,060 | +10.8% | 0.00% | – |
| Q4 2021 | $347,000 | +21.3% | 86,703 | 0.0% | 0.00% | – |
| Q3 2021 | $286,000 | -13.1% | 86,703 | 0.0% | 0.00% | – |
| Q2 2021 | $329,000 | -83.4% | 86,703 | -83.2% | 0.00% | – |
| Q1 2021 | $1,982,000 | -7.7% | 517,363 | +9.0% | 0.00% | – |
| Q4 2020 | $2,148,000 | -72.7% | 474,691 | +2.0% | 0.00% | -100.0% |
| Q3 2020 | $7,876,000 | +66.2% | 465,492 | +10.1% | 0.00% | – |
| Q2 2020 | $4,738,000 | – | 422,678 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |